Prostate Cancer Measurability of Quality Performance Indicators Version 3.0
|
|
- Julianna O’Neal’
- 7 years ago
- Views:
Transcription
1 Prostate Cancer Measurability of Quality Performance Indicators Version 3.0 To be read in conjunction with: Prostate Cancer Clinical Quality Performance Indicators V3.0 (July 2016) Prostate Cancer Data Definitions (latest published version) (For patients diagnosed from 01/07/15)
2 Measurability of Quality Performance Indicators for Prostate Cancer Please refer to the Prostate Cancer Quality Performance Indicators published by Healthcare Improvement Scotland for a full description of individual QPIs Please refer to the Prostate Cancer QPI Dataset published by ISD Scotland for a full description of individual data items Document control: This version Title Prostate Cancer Measurability of QPIs Version/Issue Number Version July 2015 (where amended or new QPIs require new data items for Effective From Author Charlotte Anthony ISD measurement this will apply for patients diagnosed from 1 st July 2016) Document Type Guidance Document status Final for publication Document Purpose To outline how QPIs should be measured using the agreed National Minimum Core Data Set Summary of changes Amendments made out-with review Revision History Version Date Status Summary of Changes QPI (s) 1.0: April /4/2012 Final Finalised following public engagement All 1.0: May /5/2012 Update to format as agreed at meeting of QPI working group 9/5/2012 All 1.0 June /6/2012 Changes to reflect updated dataset QPI June /6/2012 Changes to reflect dataset QPI 2 1.2: Dec /12/2012 Update of format for not recorded specification as requested by BM All 1.3: Feb /02/2013 Final Update of format for not recorded specification as agreed with Roger Black Jan 2013 & checked All against updated dataset 2.0: Dec /03/2013 Final Amendments made as per agreed changes following 9 month review, updated with new MDT QPI, and checked against published QPIs and dataset. 2.1: Jan /01/2014 Final Correct issues with specification not including all patients) : July /07/2014 Final Amendments made out-with review, incorporating additional data item into the dataset updating 2,4,5,8 the MDT QPI 2.3 Nov /11/2014 Final Amendments made out-with review (initial Baseline change). 5,8 2.4: Jan /01/2015 Draft Baseline review updates made 2, 4,7 & Mar /03/2015 Final Baseline review updates published 2, 4,7 & Apr /04/2015 Draft Change made out-with review following Baseline comments 2 & Apr /04/2015 Final Change made out-with review following Baseline comments 2 & May /05/2015 Final Changes made out with review following analysis 1 st and 2 nd year reporting Nov /11/2016 Final Amendments made as per agreed changes following Formal Review 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12
3 Updates from Previous Version QPI Summary of changes Nov 2016 (excluding formatting changes) Description inserted by pathology ; Numerator inserted by pathology, AND Number of Needle Cores Received (targeted) + [NUMCORESRECT]) 10; Denominator 1 change excludes to excluding, inserted or TRUS (mpmri fusion biopsy) [SPECTYPE = 1 or 3] ; NR for Numerator inserted OR [NUMCORESRECT = 99] Description inserted the following text Please note: The specifications of this QPI are separated to ensure clear measurement of patients with: (i) Intermediate risk prostate cancer who undergo MRI; and (ii) High risk prostate cancer who undergo MRI and bone scan ; Numerator (i) removed text (or alternative 2 whole body MRI evaluation) ; Denominator (i) within TNM Tumour Classification removed or T2c and inserted T2c or in the TNM Tumour Classification not coded as..., c removed from T3, T3a, T3b and T4; Denominator (ii)inserted T2c or within TNM Tumour Classification and c removed from T3, T3a, T3b and T4..., c removed from T3, T3a, T3b and T4 Description inserted of QPI document ; Numerator inserted of QPI document ; Denominator removed TRUS and inserted Transrectal Ultrasound Guided Biopsy OR 3 Transrectal Ultrasound Guided Biopsy (mpmri fusion biopsy) OR 3 QPI Title removed with newly diagnosed prostate cancer ; Description inserted the following text Please note: The specifications of this QPI are separated to ensure clear measurement of patients with:(i) Non-metastatic prostate cancer (TanyNanyM0); and (ii) Metastatic prostate cancer (TanyNanyM1). ; Numerator now split to (i) & (ii), Numerator (i) inserted non-metastatic and (TanyNanyM0); Denominator now split to (i) & (ii), Denominator (i) replaced diagnosed with to with non-metastatic 4 inserted (TanyNanyM0), inserted AND TNM Metastases Classification (Clinical) (Cancer of the Prostate) coded as : No distant metastasis Type of First Cancer Treatment not coded as Patient Died Before Treatment [cm = M0] AND; Numerator (ii) and Denominator (ii) see main document for detail; NR Denominator inserted [cm = 99] Numerator changed to Specification and inserted the following text It is recommended that where two consultants operate together on the same patient the case 6 should be counted under the Lead Surgeon. Rows Denominator, NR Numerator, NR exclusion and NR Denominator have all been deleted. QPI 7 was Hormone Therapy now Hormone Therapy and Docetaxel Chemotherapy ; QPI Title inserted and chemotherapy where appropriate and inserted the following footers * Immediate hormone therapy would be within 31 days of MDT meeting (pre-treatment). * LHRH agonist / antagonist monotherapy, dual androgen blockade or bilateral orchidectomy. * Docetaxel should be started within 90 days of first dose of hormone therapy. ; Description removed who are managed with any hormone therapy licensed in this indication as monotherapy or in combination with an anti-androgen for maximum androgen blockade, or bilateral orchidectomy. Note: Developing new LHRH agonists may be included when SMC licensing for appropriate use approved inserted and docetaxel chemotherapy and Please note: The specifications of this QPI are separated to ensure clear measurement of patients who receive (i) Immediate hormone therapy; 7 and (ii) Immediate hormone therapy and docetaxel chemotherapy. ; Numerator now split to (i) & (ii), Numerator (i) removed (LHRH agonist monotherapy, maximum androgen blockade or bilateral orchidectomy), or Orchidectomy inserted presenting with metastatic prostate cancer (TanyNanyM1), or Gonadorelin Antagonist, Orchidectomy or ; Denominator now split to (i) & (ii), Denominator (i) inserted Type of Hormone Therapy not coded as : Patient refused replaced NOT with AND Patient Entered into Clinical Trial inserted not coded as..., removed AND NOT Type of Hormone Therapy coded as Patient refused ; Numerator (ii) and Denominator (ii) see main document for detail; NR Numerator split to (i) & (ii), inserted (ii) [HORMDATE = 09/09/0909] OR [MDTDATE =09/09/0909] OR [HORMAGENT = 99] OR [CHEMAGENT = 99] OR [CHEMDATE = 09/09/0909] ; NR Exclusion split to (i) & (ii), inserted (ii) [HORMTYPE = 99] OR [CHEMAGENT = 99] OR [TRIAL = 99] Numerator (i) & (ii) inserted undergoing radical prostatectomy and measured using a validated tool** 3pads/day amended to 2 pads/day and removed OR 8 incontinent ; Denominator amended 6 months to 12 months, and 180 days to 365 days. 9 QPI ARCHIVED 10 QPI ARCHIVED 11 Inserted new QPI Early Management of Active Surveillance 12 Inserted new QPI 30 Day Mortality Following Chemotherapy QPI 6 Summary of changes May 2015 (excluding formatting changes) Numerator inserted the following text - Number of radical prostatectomies performed by each surgeon in a given year. No exclusions. Number of operations (MainOp or Op1 or Op2 or Op3 = {M611 or M612 or M613 or M614 or M619}) perfomed by each surgeon where operation date is within time period specified. NB: If clinician responsible for relevant operation is not recorded, consultant/hcp responsible for care is used instead and this should be noted. QPI Summary of changes (excluding formatting changes) April 2015 Denominator (i) changes made to exclude High Risk patients: (([ct = T2b OR T2c] AND [GTOTAL < 8] AND [PSA 20.0]) OR ([GTOTAL = 7] AND [ct <> T3 OR T3a OR T3b OR T4] AND [PSA 20.0]) OR ([PSA 10.0 AND 20.0] AND [ct <> ct3 OR ct3a OR ct3b OR ct4] AND [GTOTAL < 8]) 2 added and ( [ct = ct3 OR ct3a OR ct3b OR ct4] OR [GTOTAL = 8 OR 9 OR 10] OR ( [PSA >20] AND [PSA <> ] AND [PSA <> ] ) removed. NR for Denominator. ([ct = 99] AND ([GTOTAL < 8] OR [GTOTAL = 99]) AND ([PSA 20] OR [PSA = ] OR [PSA =
4 ])) OR ([GTOTAL = 99] AND [ct<> T3 or T3a or T3b or T3c or T4] AND ([PSA 20] OR [PSA = ] OR [PSA = ])) OR ([PSA = ] AND [ct <> T3 or T3a or T3b or T3c or T4] AND ([GTOTAL < 8] OR [GTOTAL = 99])) OR ([TYPESURG = 99] AND [RADIO <> 3] AND [BRACHYDATE = 10/10/1010]) OR ([RADIO = 99] AND [TYPESURG <> 1] AND [BRACHYDATE = 10/10/1010]) added and [ct = 99] AND [GTOTAL = 99] AND [PSA = ] OR ( [TYPESURG = 99] AND [RADIO = 99] ) OR [BRACHYDATE = 09/09/0909] removed. Changed to calculation agreed for Bladder 9-month review changed to [MDTDATE <> 10/10/1010] AND ([MDTDATE DEFTREATDATE] OR [DEFTREATDATE = 10/10/1010]) QPI Summary of changes (excluding formatting changes) March Split QPI reporting into two distinct elements. Remove OR [MAJGGRADE] = 99 OR [MINGGRADE] = 99 from NR denominator. 4 Add OR [DEFTREATDATE <> 10/10/1010] to numerator. 7 Change from 14 days to 31 days 9 Change NR for numerator to ([URIMORBID = 99] AND [BOWMORBID <> 3 OR 4 OR 5]) OR ([BOWMORBID = 99] AND [URIMORBID <> 3 OR 4 OR 5]) QPI Summary of changes (excluding formatting changes) November 2014 replace 'Retropubic prostatectomy; OR Transvesical prostatectomy' text with 'Radical prostatectomy' and remove 'M61.2 OR M61.4 OR' from calculation in 5 denominator specification replace 'Retropubic prostatectomy; OR Transvesical prostatectomy' text with 'Radical prostatectomy' and remove 'M61.2 OR M61.4 OR' from calculation in 8 denominator specification QPI Summary of changes (excluding formatting changes) July 2014 Corrected not recorded value for PSA ( ) in not recorded for denominator. Added OR ([GTOTAL = 99] AND ([MAJGGRADE] + [MINGGRADE] = 7 or 8 or 9 2 or 10)). AND [PSA <> )) 4 Amended MDT QPI 5 Remove M34.1 from denominator 8 Remove M34.1 from denominator QPI Summary of changes (excluding formatting changes) Jan Amended denominator to include patients with M1a, M1b and M1c disease. 2 Removed duplicate of denominator calculation from numerator and corrected syntax of denominator specification. 3 Removed PSA from numerator as this is not a required field on Scottish Prostate Needle Biopsy Dataset. 4 Inserted new MDT QPI measurability. 5 Previously QPI 4 6 Previously QPI 5 7 Previously QPI 6. Updated to include LHRH antagonists. 8 Previously QPI 7 9 Previously QPI 8 10 Previously QPI 9
5 QPI 1: Biopsy Procedure QPI Title: Procedure for performing prostate biopsy should be optimised. Description: Numerator: Proportion of patients with prostate cancer who undergo trans-rectal ultrasound guided (TRUS) prostate biopsy for histological diagnosis where a minimum of 10 cores are received by pathology. Number of patients with prostate cancer who undergo TRUS biopsy where a minimum of 10 cores are received by pathology. Number of Needle Cores Received (Right-Left) AND Number of Needle Cores Received (targeted) greater than or equal to 10 ([NUMCORESRECR] + [NUMCORESRECL] + [NUMCORESRECT]) 10 Denominator: All patients with prostate cancer who undergo TRUS biopsy of the prostate (Excluding patients enrolled in clinical trials, and patients with advanced (T4NanyMany) or metastatic disease (TanyNanyM1)). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis AND Type of Specimen for Histological Diagnosis (Prostate Cancer) coded as TRUS or TRUS (mpmri fusion biopsy); AND Patient Entered into Clinical Trial {Prostate Cancer} not coded as yes; AND TNM Metastases Classification (Clinical) (Cancer of the Prostate) NOT coded as: Distant metastasis; AND TNM Tumour Classification (Clinical) (Cancer of the Prostate) NOT coded as: Tumour is fixed or invades adjacent structures other than seminal vesicles [SPECTYPE = 1 or 3] AND [TRIAL <> 1] AND [ct <> T4] AND [cm <> M1 OR M1a OR M1b OR M1c] numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [NUMCORESRECR OR NUMCORESRECL = 99] OR [NUMCORESRECT = 99] exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [TRIAL = 99] OR [cm = 99] OR [ct = 99] denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [SPECTYPE = 99]
6 QPI 2: Radiological Staging QPI Title: Patients with intermediate or high risk prostate cancer who are suitable for radical treatment, should be evaluated for locally advanced, nodal or bony metastatic disease. Description: Proportion of patients with intermediate and high risk prostate cancer undergoing radical treatment who have had MRI and bone scan staging. Please note: The specifications of this QPI are separated to ensure clear measurement of patients with: (i) Intermediate risk prostate cancer who undergo MRI; and (ii) High risk prostate cancer who undergo MRI and bone scan Numerator (i) Number of patients with intermediate risk prostate cancer undergoing radical treatment who have an MRI of the prostate. Imaging Investigations Complete coded as: Complete MRI and Isotope Bone Scan or Whole Body MRI OR Incomplete MRI of Prostate only IMAGE = 1 OR 2C Denominator (i) All patients with intermediate risk prostate cancer undergoing radical treatment. (Excluding Patients unable to undergo an MRI scan, and Patients who refuse MRI) Date of Diagnosis in range specified for comparative analysis AND (TNM Tumour Classification (Clinical) (Cancer of the Prostate) coded as: T2b AND Gleason Total score coded as: less than 8 AND Prostate Specific Antigen at Diagnosis less than or equal to 20) OR Gleason Total score equal to 7 AND TNM Tumour Classification (Clinical) (Cancer of the Prostate) not T2c or T3 or T4 AND Prostate Specific Antigen at Diagnosis less than or equal to 20 OR Prostate Specific Antigen at Diagnosis greater or equal to 10 AND less than or equal to 20 AND TNM Tumour Classification (Clinical) (Cancer of the Prostate) not T2c or T3 or T4 AND Gleason Total score coded as: less than 8 AND (Type of Surgery coded as: Radical; OR External Beam Radiotherapy Course Type coded as: Radical; OR Brachytherapy Date not coded as: inapplicable ) AND Imaging Investigations Complete not coded as 2A or 95 (([ct = T2b] AND [GTOTAL < 8] AND [PSA 20.0]) OR ([GTOTAL = 7] AND [ct <> T2c OR T3 OR T3a OR T3b OR T4] AND [PSA 20.0]) OR ([PSA 10.0 AND 20.0] AND [ct <> T2c OR T3 OR T3a OR T3b OR T4] AND [GTOTAL < 8])) AND ( [TYPESURG = 1] OR [RADIO = 3] OR [BRACHYDATE <> 10/10/1010] ) AND [IMAGE <> 2A OR 95] Numerator (ii) Number of patients with high risk prostate cancer undergoing radical treatment who have an MRI of the prostate and isotope bone scan (or alternative whole body MRI evaluation). IMAGE = 1
7 Denominator (ii) All patients with high risk prostate cancer undergoing radical treatment. (Excluding Patients unable to undergo an MRI scan, and Patients who refuse MRI) Date of Diagnosis in range specified for comparative analysis AND (TNM Tumour Classification (Clinical) (Cancer of the Prostate) coded as: T2c or T3 or T3a or T3b or T4 OR Gleason Total score coded as: 8 or 9 or 10 OR Prostate Specific Antigen at Diagnosis greater than 20) AND (Type of Surgery coded as: Radical; OR External Beam Radiotherapy Course Type coded as: Radical; OR Brachytherapy Date not coded as: inapplicable ) AND Imaging Investigations Complete not coded as 2A or 95 ( [ct = T2c OR T3 OR T3a OR T3b OR T4] OR [GTOTAL = 8 OR 9 OR 10] OR ( [PSA >20] AND [PSA <> ] AND [PSA <> ] ) ) AND ( [TYPESURG = 1] OR [RADIO = 3] OR [BRACHYDATE <> 10/10/1010] ) AND [IMAGE <> 2A OR 95] numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [IMAGE = 99] exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [IMAGE = 99] denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard ([ct = 99] AND ([GTOTAL < 8] OR [GTOTAL = 99]) AND ([PSA 20] OR [PSA = ] OR [PSA = ])) OR ([GTOTAL = 99] AND [ct<> T3 or T3a or T3b or T3c or T4] AND ([PSA 20] OR [PSA = ] OR [PSA = ])) OR ([PSA = ] AND [ct <> T3 or T3a or T3b or T3c or T4] AND ([GTOTAL < 8] OR [GTOTAL = 99])) OR ([TYPESURG = 99] AND [RADIO <> 3] AND [BRACHYDATE = 10/10/1010]) OR ([RADIO = 99] AND [TYPESURG <> 1] AND [BRACHYDATE = 10/10/1010])
8 QPI 3: Pathology Reporting QPI Title: All surgical pathology reports for prostate needle biopsies should contain full pathology information to inform treatment decision making. Description: Numerator Proportion of patients who undergo needle biopsy where the pathology report contains a full set of data items (as defined by the Scottish Urological Pathologists dataset see appendix 4 of QPI document). Number of patients with prostate adenocarcinoma who undergo prostate needle biopsy where needle biopsy pathology report contains all data items (as defined in the Scottish Urological Pathologists dataset see appendix 4 of QPI document). Type of Specimen for Histological Diagnosis (Prostate Cancer) not coded as Not Recorded; AND Number of Needle Cores Received (Right- Left) not coded as Not Recorded; AND Transurethral Resection of Prostate (TURP) Weight not coded as Not Recorded; AND Prostate Specimen Tumour Type not coded as Not Recorded; AND Number of Needle Cores Involved (Right-Left) not coded as Not Recorded; AND Total Percentage of Tumour Involvement in Needle Core OR Greatest Percentage of Tumour Involvement in Needle Core not coded as Not Recorded; AND Adipose Tissue Invasion Seen not coded as Not Recorded; AND Perineural Invasion Seen not coded as Not Recorded; AND Primary Gleason Grade (Needle Biopsy) not coded as Not Recorded; AND Secondary Gleason Grade (Needle Biopsy) not coded as Not Recorded; AND Gleason Total Score (Needle Biopsy) not coded as Not Recorded. [SPECTYPE <> 99] AND [NUMCORESRECR <> 99] AND [NUMCORESRECL <> 99] AND [TURPWT <> ] AND [TUMTYPE <> 99] AND [NUMCORESINVR <> 99] AND [NUMCORESINVL <> 99] AND ( [TOTPERCINV OR GRTPERCINV <> 999] ) AND [ADIPOSE <> 99] AND [PERINEURAL <> 99] AND [MAJGGRADE <> 99] AND [MINGGRADE <> 99] AND [GTOTAL <> 99] Denominator All patients with prostate adenocarcinoma who undergo prostate needle biopsy (No exclusions). Date of Diagnosis in range specified for comparative analysis AND Type of Specimen for Histological Diagnosis (Prostate Cancer) coded as: Transrectal Ultrasound Guided Biopsy OR Transrectal Ultrasound Guided Biopsy (mpmri fusion biopsy) [SPECTYPE = 1 OR 3] numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target N/A (patients not recorded for the numerator are included in the numerator not met category for this standard) exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [SPECTYPE = 99]
9 QPI 4: Multi-Disciplinary Team Meeting (MDT) QPI Title: Patients should be discussed by a multi-disciplinary team prior to definitive treatment. Description: Proportion of patients with prostate cancer who are discussed at MDT meeting before definitive treatment. Please note: The specifications of this QPI are separated to ensure clear measurement of patients with: (i) Non-metastatic prostate cancer (TanyNanyM0); and (ii) Metastatic prostate cancer (TanyNanyM1). Numerator (i) Number of patients with non-metastatic prostate cancer (TanyNanyM0) discussed at the MDT before definitive treatment. Date Discussed by Care Team (MDT) not coded as not applicable AND Date Discussed by Care Team (MDT) less than or equal to Date of Definitive Treatment OR Date of Definitive Treatment Equal to not applicable [MDTDATE <> 10/10/1010] AND ([MDTDATE DEFTREATDATE] OR [DEFTREATDATE = 10/10/1010]) Denominator (i) All patients with non-metastatic prostate cancer (TanyNanyM0) (Excluding patients who died before first treatment). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; AND TNM Metastases Classification (Clinical) (Cancer of the Prostate) coded as: No distant metastasis AND Type of First Cancer Treatment not coded as Patient Died Before Treatment; [cm = M0 ] AND [FIRSTTREATMODE <> 14]; Numerator (ii) Number of patients with metastatic prostate cancer (TanyNanyM1) discussed at the MDT within 4 weeks of commencing treatment. Date Discussed by Care Team (MDT) not coded as not applicable; AND Date Discussed by Care Team (MDT) minus Date of Definitive Treatment less than or equal to 28 days; OR Date of Definitive Treatment Equal to not applicable [MDTDATE <> 10/10/1010] AND ([MDTDATE DEFTREATDATE 28 days] OR [DEFTREATDATE = 10/10/1010]) Denominator (ii) All patients with metastatic prostate cancer (TanyNanyM1) (Excluding patients who died before first treatment). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; AND TNM Metastases Classification (Clinical) (Cancer of the Prostate) coded as: Distant metastasis; OR Non-regional lymph node(s); OR Bone(s); OR Other site(s); AND Type of First Cancer Treatment not coded as Patient Died Before Treatment; [cm = M1 OR M1a OR M1b OR M1c] AND [FIRSTTREATMODE <> 14]; numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MDTDATE = 09/09/0909] OR [DEFTREATDATE = 09/09/0909]
10 exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [FIRSTTREATMODE = 99] denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [cm = 99]
11 QPI 5: Surgical Margins QPI Title: Organ confined prostate cancers which are surgically treated with radical prostatectomy should be completely excised. Description: Numerator Proportion of patients with pathologically confirmed, organ confined (stage pt2) prostate cancer who undergo radical prostatectomy in which tumour is present at the margin, i.e. positive surgical margin. Number of patients with stage pt2 prostate cancer who underwent radical prostatectomy in which tumour is present at the margin. Margin Status (Prostatectomy) coded as: Positive [MARGIN = 1] Denominator All patients with stage pt2 prostate cancer who underwent radical prostatectomy (No exclusions). Date of Diagnosis in range specified for comparative analysis, AND TNM Tumour Classification (Pathological) (Prostate) coded as: Tumour confined within the prostate; OR Tumour involves one half of one lobe or less; OR Tumour involves more than half of one lobe but not both lobes; OR Tumour involves both lobes, AND Definitive Operative Procedure coded as: Radical prostatectomy [pt= pt2 OR pt2a OR pt2b OR pt2c] AND [OPCODE = M61.1] numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [MARGIN = 99] exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [pt = 99] OR [OPCODE = 99]
12 QPI 6: Volume of Cases Per Surgeon QPI Title: Description: Specification Surgery should be performed by surgeons who perform the procedure routinely. Number of radical prostatectomy procedures performed by a surgeon over a 1 year period. Number of radical prostatectomies performed by each surgeon in a given year (No exclusions). Number of operations (MainOp or Op1 or Op2 or Op3 = {M611 or M612 or M613 or M614 or M619}) perfomed by each surgeon where operation date is within time period specified. NB: If clinician responsible for relevant operation is not recorded, consultant/hcp responsible for care is used instead and this should be noted. It is recommended that where two consultants operate together on the same patient the case should be counted under the Lead Surgeon.
13 QPI 7: Hormone Therapy and Docetaxel Chemotherapy QPI Title: Patients with metastatic prostate cancer should undergo immediate hormone therapy, and chemotherapy where appropriate **. Description: Proportion of patients with metastatic prostate cancer (TanyNanyM1) who undergo immediate management with hormone therapy, and docetaxel chemotherapy. Please note: The specifications of this QPI are separated to ensure clear measurement of patients who receive: (i) (ii) Immediate hormone therapy; and Immediate hormone therapy and docetaxel chemotherapy. Numerator (i) Number of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy. Date Treatment Started (Hormone Therapy) minus Date Discussed by Care Team is less than or equal to 31 days, AND Hormonal Therapy Agent coded as: Gonadorelin Agonist (GnRH), or Gonadorelin Antagonist or Orchidectomy or Maximum Androgen Blockade (MAB). [HORMDATE - MDTDATE 31 days] AND [HORMAGENT = 1 OR 2 OR 7 OR 10] Denominator (i) All patients presenting with metastatic prostate cancer (TanyNanyM1). (Excluding patients documented to have refused immediate hormone therapy, and patients enrolled in clinical trials). Date of Diagnosis in range specified for comparative analysis, AND TNM Metastases Classification (Clinical) (Cancer of the Prostate) coded as: Distant metastasis; OR Non-regional lymph node(s); OR Bone(s); OR Other site(s), AND Type of Hormone Therapy not coded as: Patient refused AND Patient Entered into Clinical Trial {Prostate Cancer} not coded as: Yes. [cm = M1 OR M1a OR M1b OR M1c] AND [HORMTYPE <> 95] AND [TRIAL <> 1] Numerator (ii) Number of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy and docetaxel chemotherapy. Date Treatment Started (Hormone Therapy) minus Date Discussed by Care Team is less than or equal to 31 days, AND Hormonal Therapy Agent coded as: Gonadorelin Agonist (GnRH) or Gonadorelin Antagonist or Orchidectomy or Maximum Androgen Blockade (MAB), AND Chemotherapy Agent coded as: docetaxel chemotherapy AND Date Treatment Started (Chemotherapy) minus Date Treatment Started (Hormone Therapy) is less than or equal to 90 days. [HORMDATE - MDTDATE 31 days] AND [HORMAGENT = 1 OR 2 OR 7 OR 10] AND [CHEMAGENT = 1] AND [CHEMDATE HORMDATE 90 days] Immediate hormone therapy would be within 31 days of MDT meeting (pre-treatment). LHRH agonist / antagonist monotherapy, dual androgen blockade or bilateral orchidectomy. ** Docetaxel should be started within 90 days of first dose of hormone therapy.
14 Denominator (ii) All patients presenting with metastatic prostate cancer (TanyNanyM1). (Excluding patients documented to have refused immediate hormone therapy, patients documented to have refused chemotherapy and patients enrolled in clinical trials). Date of Diagnosis in range specified for comparative analysis, AND TNM Metastases Classification (Clinical) (Cancer of the Prostate) coded as: Distant metastasis; OR Non-regional lymph node(s); OR Bone(s); OR Other site(s), AND Type of Hormone Therapy not coded as: Patient refused AND Chemotherapy Agent not coded as: Patient refused AND Patient Entered into Clinical Trial {Prostate Cancer} not coded as: Yes. [cm = M1 OR M1a OR M1b OR M1c] AND [HORMTYPE <> 95] AND [CHEMAGENT <> 95] AND [TRIAL <> 1] numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target (i) [HORMDATE = 09/09/0909] OR [MDTDATE =09/09/0909] OR [HORMAGENT = 99] (ii) [HORMDATE = 09/09/0909] OR [MDTDATE =09/09/0909] OR [HORMAGENT = 99] OR [CHEMAGENT = 99] OR [CHEMDATE = 09/09/0909] exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. (i) [HORMTYPE = 99] OR [TRIAL = 99] (ii) [HORMTYPE = 99] OR [CHEMAGENT = 99] OR [TRIAL = 99] denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [cm = 99]
15 QPI 8: Post Surgical Incontinence QPI Title: Post surgical incontinence for patients with prostate cancer should be minimised. Description: Proportion of prostate cancer patients who undergo radical prostatectomy with post surgical incontinence approximately 1 year (between 10 and 14 months) after surgery. Numerator (i) Number of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (> 0 pads per day measured using a validated tool**) at 1 year (10-14 months) post radical prostatectomy. Post-Surgical Continence at One Year coded as: 1 pad/day; OR 2 pads/day [CONTINENT = 2 OR 3 ] Numerator (ii) Number of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 1 pad per day measured using a validated tool) at 1 year (10-14 months) post radical prostatectomy. Post-Surgical Continence at One Year coded as 2pads/day [CONTINENT = 3 ] Denominator All patients with prostate cancer undergoing radical prostatectomy. (Excluding patients who undergo salvage prostatectomy and patients who receive adjuvant radiotherapy within 12 months of surgery). Date of Diagnosis in range specified for comparative analysis, AND Definitive Operative Procedure coded as: Radical prostatectomy, AND Type of Surgery NOT coded as: Salvage Surgery, AND External Beam Radiotherapy Course Type NOT coded as: Adjuvant AND Date Treatment Completed (External Beam Radiotherapy) minus Date of Definitive Surgery NOT within 12 months (365 days) [OPCODE = M61.1] AND [TYPESURG <> 3] AND NOT ( [RADIO = 2] AND [RCOMPDATE - SURGDATE < 365] ) numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [CONTINENT = 99] exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. [TYPESURG = 99] OR [RADIO = 99] OR [RCOMPDATE = 09/09/0909] OR [SURGDATE = 09/09/0909] denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [OPCODE = 99]
16 QPI 11: Early Management of Active Surveillance QPI Title: Description: Men under active surveillance for prostate cancer should undergo appropriate investigations at the clinically relevant timings. Proportion of men with prostate cancer under active surveillance who undergo multiparametric MRI within 6 months, and prostate re-biopsy within 14 months of diagnosis. Please note: The specifications of this QPI are separated to ensure clear measurement of patients who have undergone: (i) (ii) Multiparametric MRI within 6 months of diagnosis; and Prostate re-biopsy within 14 months of diagnosis. Numerator (i) Number of patients with prostate cancer under active surveillance who undergo multiparametric MRI within 6 months of diagnosis. Date of Multiparametric MRI Scan (Surveillance) minus Date of Diagnosis is less than or equal to 182 days [MPDATESURV DIAGDATE 182 days] Denominator (i) All patients with prostate cancer under active surveillance (Excluding patients unable to undergo an MRI scan and patients who refuse MRI). Date of Diagnosis in range specified for comparative analysis, AND Type of First Cancer Treatment coded as: Active Surveillance AND Multiparametric MRI Scan (Surveillance) not coded as: Patient unable to undergo MRI scan or Patient refused MRI. [FIRSTTREATMODE = 12] AND [MPMRISURV <> 3 OR 95] Numerator (ii) Number of patients with prostate cancer under active surveillance who undergo transrectal ultrasound guided (TRUS) prostate re-biopsy within 14 months of diagnosis. Date of TRUS Re-Biopsy minus Date of Diagnosis is less than or equal to 427 days [REBIODATE DIAGDATE 427 days] Denominator (ii) All patients with prostate cancer under active surveillance (Excluding patients who undergo radical treatment within 14 months of diagnosis and patients who refuse biopsy). Date of Diagnosis in range specified for comparative analysis, AND Type of First Cancer Treatment coded as: Active Surveillance AND Trus Re-biopsy is not coded as Patient has undergone radical treatment or Patient refused biopsy. [FIRSTTREATMODE = 12] AND [REBIOPSY <> 3 or 95]
17 numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target (i) [MPDATESURV = 09/09/0909] OR [DIAGDATE = 09/09/0909] (ii) [REBIODATE = 09/09/0909] OR [DIAGDATE = 09/09/0909] exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. (i) [MPMRISURV = 99] (ii) [REBIOPSY = 99] denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard (i) and (ii) [FIRSTTREATMODE = 99]
18 QPI 12: 30 Day Mortality following Chemotherapy QPI Title: Description: 30 day mortality following chemotherapy treatment for prostate cancer. Proportion of patients with prostate cancer who die within 30 days of chemotherapy. Numerator: Number of patients with prostate cancer who undergo chemotherapy that die within 30 days of treatment. Date of Death is not coded as inapplicable and is within 30 days of date of the first day of the last cycle of chemotherapy [DOD - CHEMENDATE 30]) AND [DOD <> 10/10/1010] Denominator: All patients with prostate cancer who undergo chemotherapy (No exclusions). Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; AND Chemotherapy Agent (Prostate Cancer) is coded as Docetaxel or Other [CHEMAGENT = 1 or 2] Not recorded for numerator Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target [CHEMENDATE = 09/09/0909] OR [DOD = 09/09/0909] Not recorded for exclusion Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. N/A Not recorded for denominator Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard [CHEMAGENT = 99]
A918: Prostate: adenocarcinoma
A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationNewly Diagnosed Prostate Cancer: Understanding Your Risk
Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationDIAGNOSIS OF PROSTATE CANCER
DIAGNOSIS OF PROSTATE CANCER Determining the presence of prostate cancer generally involves a series of tests and exams. Before starting the testing process, the physician will ask questions about the
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationEndometrial Cancer. Measurability of Quality Performance Indicators Version 2.0
Endometrial Cancer Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Endometrial Cancer QPIs Final Publication v2 Endometrial QPI Dataset (latest published version)
More informationScottish Cancer Taskforce National Cancer Quality Steering Group. Prostate Cancer Clinical Quality Performance Indicators Engagement Document
Scottish Cancer Taskforce National Cancer Quality Steering Group Prostate Cancer Clinical Quality Performance Indicators Engagement Document May 2016 Contents Page 1. National Cancer Quality Programme...
More informationProstate Cancer In-Depth
Prostate Cancer In-Depth Introduction Prostate cancer is the most common visceral malignancy among American men. In the year 2003, there are expected to be 220,000 new cases and nearly 29,000 deaths in
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationGENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.
GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate
More informationFor further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.
Prostate Cancer For many older men, prostate cancer may be present but never cause symptoms or problems and many men will die with their prostate cancer rather than of their prostate cancer. Yet it remains
More informationPATIENT GUIDE. Localized Prostate Cancer
PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationUnderstanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives.
Understanding Prostate Cancer The Urology Group Guide for Newly Diagnosed Patients Advanced Care. Improving Lives. UNDERSTANDING PROSTATE CANCER The Urology Group has created this publication to provide
More informationLymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationPROSTATE CANCER. Diagnosis and Treatment
Diagnosis and Treatment Table of Contents Introduction... 1 Patient and Coach Information... 1 About Your Prostate... 1 What You Should Know About Prostate Cancer... 2 Screening and Diagnosis... 2 Digital
More informationProstate cancer A guide for newly diagnosed men
Prostate cancer A guide for newly diagnosed men 2 Prostate cancer A guide for newly diagnosed men About this booklet This booklet is for men who have recently been diagnosed with prostate cancer. It is
More informationProstate Cancer Management Clinical Guidelines
Royal College of Surgeons in Ireland e-publications@rcsi Surgery (The Colles Institute) Surgical Clinical Guidelines Surgery (The Colles Institute) 1-2-2002 Prostate Cancer Management Clinical Guidelines
More informationLocalised prostate cancer
Diagnosis Specialist Nurses 0800 074 8383 prostatecanceruk.org 1 Localised prostate cancer In this fact sheet: What is localised prostate cancer? How is localised prostate cancer diagnosed? What do my
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationYour Health Matters. Localized Prostate Cancer and Its Treatment
Your Health Matters Localized Prostate Cancer and Its Treatment Greetings! Understanding prostate cancer and choosing among the various treatment options can be a difficult and anxiety-arousing process.
More informationPROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
More informationProstate Cancer: National Collaborating Centre for Cancer. diagnosis and treatment. Clinical Guideline. January 2014. Prostate Cancer.
National Collaborating Centre for Cancer Prostate Cancer Prostate Cancer: diagnosis and treatment Clinical Guideline Full Guideline January 2014 Final version Commissioned by the National Institute for
More informationUnderstanding Locally-Advanced Prostate Cancer
Understanding Locally-Advanced Prostate Cancer This booklet is to help you and your family understand what it means if you have been diagnosed as having locally-advanced prostate cancer. It gives an outline
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More information一 本 共 識 依 下 列 參 考 資 料 修 改 版 本 : 1. NCCN Clinical Practice Guidelines in Oncology- Prostate cancer V.2.2014
一 本 共 識 依 下 列 參 考 資 料 修 改 版 本 : 1. NCCN Clinical Practice in Oncology- Prostate cancer V.2.2014 二 制 訂 人 員 : 泌 尿 外 科 : 鍾 旭 東 醫 師 蔡 宗 佑 醫 師 洪 順 發 醫 師 腫 瘤 內 科 : 蕭 吉 晃 醫 師 放 射 腫 瘤 : 熊 佩 韋 醫 師 解 剖 病 理 : 蔡 建
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationProstate Cancer with Bone Metastasis: the Consideration of Radiotherapy
Prostate Cancer with Bone Metastasis: the Consideration of Radiotherapy Case Number: RT2009-19(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present a case
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationClinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175
Prostate cancer: diagnosis and management Clinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175 NICE 2014. All rights reserved. Contents Introduction... 4 Drug recommendations... 5 Patient-centred
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More informationProstate Cancer & Its Treatment
Your Health Matters Prostate Cancer & Its Treatment By the UCSF Medical Center Prostate Cancer Advocates Greetings! From our personal experience in dealing with our own prostate cancers, we UCSF Patient
More informationTreatment Routes in Prostate Cancer Urological Cancers SSCRG
1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.
More informationProstate Cancer. Patient Information
Prostate Cancer Patient Information 1 The Prostate & Prostate Cancer The prostate is a small gland in the male reproductive system, approximately the size and shape of a walnut. It is located directly
More informationLocally advanced prostate cancer
Diagnosis Specialist Nurses 0800 074 8383 prostatecanceruk.org 1 Locally advanced prostate cancer In this fact sheet: What is locally advanced prostate cancer? How is locally advanced prostate cancer diagnosed?
More informationRole of MRI in the Diagnosis of Prostate Cancer, A Proposal
Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth
More informationPrognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology
Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology Authors Key words C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel Prognostic
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationA to Z of medical words
Notes Specialist Nurses 0800 074 8383 A to Z of medical words 1 This fact sheet explains some of the medical words you might come across when you are finding out about prostate problems and prostate cancer.
More informationReport with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
More informationA Woman s Guide to Prostate Cancer Treatment
A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate
More informationNational Bowel Cancer Audit Report 2008 Public and Executive Summary
National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland
More informationTherapies for Prostate Cancer and Treatment Selection
Prostatic Diseases Therapies for Prostate Cancer and Treatment Selection JMAJ 47(12): 555 560, 2004 Yoichi ARAI Professor and Chairman, Department of Urology, Tohoku University Graduate School of Medicine
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationPSA screening: Controversies and Guidelines
PSA screening: Controversies and Guidelines John Phillips, MD, FACS Department of Urology Urology Center of Westchester New York Medical College Historical PerspecGve Cancer of the prostate, although rare,
More informationRunning Head: PROSTATE CANCER TREATMENTS AND CASE STUDY 1. Prostate Cancer: Treatments and Case Study
Running Head: PROSTATE CANCER TREATMENTS AND CASE STUDY 1 Prostate Cancer: Treatments and Case Study November 13, 2012 PROSTATE CANCER 2 Abstract Prostate cancer affected 192,280 men in the United States
More informationAfter Diagnosis: Prostate Cancer. Understanding Your Treatment Options
After Diagnosis: Prostate Cancer Understanding Your Treatment Options What s inside How will this booklet help me?... 3 What is the prostate?... 4 What is prostate cancer?... 4 Who gets prostate cancer?...
More informationAdvanced prostate cancer
1 Advanced prostate cancer In this fact sheet: What is advanced (metastatic) prostate cancer? What tests are used to diagnose advanced prostate cancer? What do my test results mean? What are my treatment
More informationRoswell Park scientists and clinicians:
The Prostate Cancer Center at Roswell Park Connects You to Nationally Recognized Experts for State-of-the-Art Treatment Options and Compassionate, Evidence-based Care Founded in 1898, Roswell Park Cancer
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationThe Business of Prostate Cancer Care: A Clinician-Researcher s Perspective
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California
More informationSIGNPOSTS. Along the Pathway of Prostate Cancer. Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer
SIGNPOSTS Along the Pathway of Prostate Cancer Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer Your journey is unique like you. Signposts along the pathway can show you where you
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationAdvanced prostate cancer
Diagnosis Helpline 0800 074 8383 prostatecanceruk.org 1 Advanced prostate cancer In this fact sheet: What is advanced (metastatic) prostate cancer? What tests are used to diagnose advanced prostate cancer?
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationBard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers
Bard: Prostate Cancer Treatment Bard: Pelvic Organ Prolapse Prostate Cancer An overview of Pelvic Treatment Organ Prolapse Information and Answers A Brief Overview Prostate Anatomy The prostate gland,
More informationLIvING WITH Prostate Cancer
Living with Prostate Cancer A Common Cancer in Men If you ve been diagnosed with prostate cancer, it s normal to be concerned about your future. It may help you to know that this disease can often be cured
More informationTreating Localized Prostate Cancer A Review of the Research for Adults
Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized
More informationHow is Prostate Cancer Diagnosed?
Prostate cancer: English Prostate cancer This fact sheet is about how prostate cancer is diagnosed and treated. We also have fact sheets in your language about chemotherapy, radiotherapy, surgery, side
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam,
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationProstate cancer. A guide for men who ve just been diagnosed
Prostate cancer A guide for men who ve just been diagnosed 2 Prostate cancer A guide for men who ve just been diagnosed About this booklet This booklet is for men who ve recently been diagnosed with prostate
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationCancer doesn t care but we do. 2010 Cancer Annual Report
Cancer doesn t care but we do. 2010 Cancer Annual Report The Cancer Committee of CHRISTUS St. Patrick Hospital is proud to present its 2010 Annual Report. The Community Hospital Comprehensive Cancer Program
More informationSCA CLINICAL PRACTICE GUIDELINE FOR PROSTATE CANCER
Saskatchewan Cancer Agency A healthy population free from cancer SCA CLINICAL PRACTICE GUIDELINE FOR PROSTATE CANCER Original Guideline date: March 2002 Update(s): October 2004, October 2008 1. General
More informationProstate Cancer Guide. A resource to help answer your questions about prostate cancer
Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online
More informationProstate cancer: diagnosis and treatment
Prostate cancer: diagnosis and treatment Update of clinical guideline 58 Appendix J: Sections from NICE clinical guideline 58 (008) that have been removed Appendix K: Recommendations from NICE clinical
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More informationU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Cancer Institute What You Need TM To Know About Prostate Cancer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health For more publications This is only one of many free booklets
More informationProstate Cancer. What is cancer?
What is cancer? Prostate Cancer The body is made up of trillions of living cells. Normal body cells grow, divide into new cells, and die in an orderly way. During the early years of a person s life, normal
More informationProstate Cancer: A Primer for Health-System Pharmacists
Prostate Cancer: A Primer for Health-System Pharmacists Prostate Cancer: A Primer for Health-System Pharmacists Accreditation Temple University School of Pharmacy, Division of Continuing Pharmaceutical
More informationDOCTOr. Doctor to HIGHLIGHTS. issue NO. 3 VOLuMe NO. 1
Doctor to DOCTOr issue NO. 3 VOLuMe NO. 1 PROSTATE CANCER is the most common cancer in men, with 233,000 new cases diagnosed per year. Although prostate cancer remains the second leading cause of cancer
More informationJurisdiction Virginia
PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Prolaris Prostate Cancer Genomic Assay (DL35629) Please note: This is a Proposed/Draft policy. Proposed/Draft LCDs are works in progress that are
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationProstate Cancer Action Plan: Choosing the treatment that s right for you
Prostate Cancer Action Plan: Choosing the treatment that s right for you Segment 1: Introduction Trust me, there's a better way to choose a treatment for your prostate cancer. Watching this program is
More informationHEALTH NEWS PROSTATE CANCER THE PROSTATE
HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized
More informationSummary 1. KEY FINDINGS The Office of Technology Assessment (OTA) concludes that research has not yet been completed to determine CHAPTER
CHAPTER 1 Summary 1 rostate cancer is a common and serious malignancy among Medicare-age men. 1 In 1995, 244,000 new cases and 40,400 deaths are anticipated from this disease; men age 65 and older bear
More informationProstate Cancer in Older Men
CHAPTER 2 Prostate Cancer in Older Men rostate cancer is a major health problem in the United States. In 1995, 244,000 new cases (up 44,000 from 1994) of prostate cancer and 40,400 deaths (up 2,400 from
More informationprostate cancer: A Success Story
prostate cancer: A Success Story Prostate cancer is the most common cancer in human beings. That is, even though prostate cancer occurs only in men, the number of men with prostate cancer exceeds the combined
More informationUnderstanding Prostate Cancer
Understanding Prostate Cancer A guide for men with cancer, their families and friends Cancer information www.cancercouncil.com.au Understanding Prostate Cancer A guide for men with cancer, their families
More informationThe Prognosis and Survival Rates For Localized Prostate Cancer
WHITE PAPER Prostate Cancer and Stereotactic Radiosurgery I. Introduction This white paper will focus on carcinoma of the prostate with sections one though six (I-VI) comprising a general review of prostatic
More informationProstate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?
Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Stacy Loeb, Edward M. Schaeffer, Bruce J. Trock, Jonathan I. Epstein, Elizabeth B. Humphreys, and Patrick C.
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More informationPCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
More informationA start to help you understand prostate cancer
A start to help you understand prostate cancer If you are reading this because you have worries or concerns about yourself or someone you know then the best thing to do is make an appointment with your
More informationHow CanCer becomes critical in the claims
How CanCer becomes critical in the claims arena Cancer is a disease in which cells in your body grow in an uncontrolled way and form a lump called a tumour. In a healthy individual cells grow and reproduce
More information